Months after cancer drug trial, Merus agrees to be bought at 41% premium Post author:tdkpropmart@gmail.com Post published:2025-09-29 Post category:ट्रेडिंग Post comments:0 Comments Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug. Source link You Might Also Like Why Nvidia, Broadcom and other highflying stocks are especially risky now 2025-10-01 Meta’s new AI glasses impressed investors — but 3 things stop them from going mainstream 2025-09-19 French finances priced as risky as Italy’s after government collapses 2025-09-09 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment.
